Cwm LLC Buys 18,519 Shares of Kenvue Inc. (NYSE:KVUE)

Cwm LLC grew its stake in shares of Kenvue Inc. (NYSE:KVUE) by 142.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,488 shares of the company’s stock after buying an additional 18,519 shares during the period. Cwm LLC’s holdings in Kenvue were worth $678,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in KVUE. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in Kenvue by 20.0% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 164,176 shares of the company’s stock valued at $3,535,000 after purchasing an additional 27,330 shares in the last quarter. Nicholas Hoffman & Company LLC. lifted its stake in shares of Kenvue by 100.3% during the 4th quarter. Nicholas Hoffman & Company LLC. now owns 50,783 shares of the company’s stock valued at $1,093,000 after buying an additional 25,430 shares in the last quarter. Verdence Capital Advisors LLC bought a new position in Kenvue in the 4th quarter worth $582,000. Calamos Wealth Management LLC purchased a new stake in Kenvue in the 4th quarter worth $204,000. Finally, Beaumont Financial Advisors LLC increased its stake in Kenvue by 3.0% in the 4th quarter. Beaumont Financial Advisors LLC now owns 17,532 shares of the company’s stock worth $377,000 after buying an additional 509 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Royal Bank of Canada lowered their price objective on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. Sanford C. Bernstein initiated coverage on Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target for the company. The Goldman Sachs Group assumed coverage on shares of Kenvue in a report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective for the company. JPMorgan Chase & Co. lowered their target price on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 9th. Finally, William Blair started coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They set a “market perform” rating for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Kenvue has a consensus rating of “Hold” and a consensus price target of $24.85.

Kenvue Trading Up 1.1 %

Shares of NYSE:KVUE opened at $19.06 on Tuesday. Kenvue Inc. has a 12 month low of $17.82 and a 12 month high of $27.80. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69. The company has a 50-day moving average price of $19.84 and a 200 day moving average price of $20.14.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.03. The business had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The firm’s revenue was down 2.7% compared to the same quarter last year. As a group, research analysts expect that Kenvue Inc. will post 1.15 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 4.20%. The ex-dividend date is Tuesday, May 7th.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.